Futibatinib Patent Expiration

Futibatinib is used for treating intrahepatic cholangiocarcinoma. It was first introduced by Taiho Oncology Inc in its drug Lytgobi on Sep 30, 2022.

Futibatinib Patents

Given below is the list of patents protecting Futibatinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Lytgobi	US11833151	Pharmaceutical composition including sodium alkyl sulfate	Nov 05, 2039	Taiho Oncology
Lytgobi	US10434103	Crystal of 3,5-disubstituted benzene alkynyl compound	Mar 31, 2036	Taiho Oncology
Lytgobi	US9108973	3,5-disubstituted alkynylbenzene compound and salt thereof	Feb 23, 2033	Taiho Oncology

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List